Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirentelimab in eosinophilic duodenitis
NCT04856891Phase 3Completed
- Sponsor
- Allakos Inc.
- Start
- May 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of lirentelimab in eosinophilic duodenitis (EoD), sponsored by Allakos Inc.. Started May 2021; status: completed.
02
Drugs
lirentelimab
03
Conditions
eosinophilic duodenitis (EoD)
Beyond the preview
Go deeper on NCT04856891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856891.